A61K 47/6887
Antibody-chelate conjugates using chelates for therapeutic purposes
Official title: {Antibody-chelate conjugates using chelates for therapeutic purposes (radioactive substances, e.g. for use in radio diagnosis or radiotherapy, A61K51/10; antibody-chelates for use in MRI A61K49/14)}
A61K47/6887 (Antibody-chelate conjugates using chelates for therapeutic purposes) appears on 70 US grants and 40 published applications in this corpus.
Search patents in A61K- Granted patents
- 70
- Published applications
- 40
- Assignees
- 49
- Inventors
- 165
- Latest grant
- 4 Feb 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 2 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 5 | 0 |
| 1992 | 4 | 0 |
| 1993 | 3 | 0 |
| 1994 | 4 | 0 |
| 1995 | 1 | 0 |
| 1996 | 8 | 0 |
| 1997 | 6 | 0 |
| 1998 | 4 | 0 |
| 1999 | 4 | 0 |
| 2000 | 2 | 0 |
| 2001 | 3 | 0 |
| 2002 | 2 | 4 |
| 2003 | 0 | 4 |
| 2004 | 2 | 1 |
| 2005 | 1 | 1 |
| 2006 | 2 | 2 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 1 | 0 |
| 2016 | 0 | 1 |
| 2017 | 1 | 1 |
| 2018 | 0 | 0 |
| 2019 | 1 | 5 |
| 2020 | 0 | 4 |
| 2021 | 5 | 3 |
| 2022 | 3 | 5 |
| 2023 | 2 | 2 |
| 2024 | 1 | 3 |
| 2025 | 1 | 2 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- C-terminal lysine conjugated immunoglobulins4 Feb 2025US 12,214,050 B2Eisai R&D Management Co., Ltd.
- Composite polypeptide having a metal binding motif and molecular construct comprising the same12 Mar 2024US 11,926,678 B2Immunwork Inc.
- Therapeutic molecules5 Sep 2023US 11,746,158 B2Crescendo Biologics Limited
- Modified antibody and radioactive metal-labelled antibody18 Jul 2023US 11,701,440 B2National University Corporation Chiba University
- Site-specific conjugation to antibody lysine residues with solid-phase immobilized microbial transglutaminase MTG and MTG in solution26 Jul 2022US 11,396,649 B2Paul Scherrer Institut
- Metal-based antibody-drug conjugates and methods of making and using thereof20 Aug 2026US 2026/0241028 A1
- Nanoparticle for use in a prophylaxis or in a treatment of a calcification of bruchs membrane and drusen23 Oct 2025US 2025/0325695 A1Universitat Munster
- Ptk7 binding agents, conjugates thereof and methods of using the same10 Apr 2025US 2025/0115680 A1ProfoundBio US Co.
- Preparatory process7 Nov 2024US 2024/0366780 A1Telix Pharmaceuticals (Innovations) Pty Ltd.
- Site-specific conjugation to antibody lysine residues with solid-phase immobilized microbial transglutaminase mtg and mtg in solution22 Aug 2024US 2024/0279634 A1Paul Scherrer Institut
Most cited
By later US patents
- Macrocyclic bifunctional chelating agents128US 4,678,667 A501 Regents of the University of California · 1987
- Pretargeting methods and compounds125US 6,217,869 B1NeoRx Corporation · 2001
- Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules85US 4,732,864 AE. I. Du Pont de Nemours and Company · 1988
- Metal radionuclide chelating compounds for improved chelation kinetics79US 4,988,496 ANeoRx Corporation · 1991
- Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies77US 4,994,560 AThe Dow Chemical Company · 1991